In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
Identifieur interne : 000822 ( PascalFrancis/Corpus ); précédent : 000821; suivant : 000823In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
Auteurs : F. Chen ; K. H. Chan ; Y. Jiang ; R. Y. T. Kao ; H. T. Lu ; K. W. Fan ; V. C. C. Cheng ; W. H. W. Tsui ; I. F. N. Hung ; T. S. W. Lee ; Y. Guan ; J. S. M. Peiris ; K. Y. YuenSource :
- Journal of clinical virology [ 1386-6532 ] ; 2004.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-la, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 04-0464714 INIST |
---|---|
ET : | In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds |
AU : | CHEN (F.); CHAN (K. H.); JIANG (Y.); KAO (R. Y. T.); LU (H. T.); FAN (K. W.); CHENG (V. C. C.); TSUI (W. H. W.); HUNG (I. F. N.); LEE (T. S. W.); GUAN (Y.); PEIRIS (J. S. M.); YUEN (K. Y.) |
AF : | Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road/Hong-Kong (1 aut., 5 aut., 6 aut.); Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital/Hong-Kong (2 aut., 4 aut., 7 aut., 8 aut., 9 aut., 10 aut., 11 aut., 12 aut., 13 aut.); Department of Biology, Hong Kong Baptist University, Kowloon Tong/Hong-Kong (3 aut.) |
DT : | Publication en série; Courte communication, note brève; Niveau analytique |
SO : | Journal of clinical virology; ISSN 1386-6532; Pays-Bas; Da. 2004; Vol. 31; No. 1; Pp. 69-75; Bibl. 24 ref. |
LA : | Anglais |
EA : | Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-la, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics. |
CC : | 002A05C10; 002B05C02J |
FD : | Coronavirus; In vitro; Test sensibilité médicamenteuse; Sensibilité; Isolat clinique; Antiviral; Grave; Malade état grave; Aigu; Syndrome respiratoire aigu sévère; Voie respiratoire; Epidémie; Microbiologie; Virologie; Forme grave; Virus syndrome respiratoire aigu sévère |
FG : | Coronaviridae; Nidovirales; Virus; Virose; Infection; Appareil respiratoire pathologie; Poumon pathologie; Appareil respiratoire |
ED : | Coronavirus; In vitro; Drug susceptibility test; Sensitivity; Clinical isolate; Antiviral; Severe; Critically ill; Acute; Severe acute respiratory syndrome; Respiratory tract; Epidemic; Microbiology; Virology; Severe acute respiratory syndrome virus |
EG : | Coronaviridae; Nidovirales; Virus; Viral disease; Infection; Respiratory disease; Lung disease; Respiratory system |
SD : | Coronavirus; In vitro; Prueba sensibilidad medicamentosa; Sensibilidad; Aislado clinico; Antiviral; Grave; Enfermo estado grave; Agudo; Síndrome respiratorio agudo severo; Vía respiratoria; Epidemia; Microbiología; Virología; Severe acute respiratory syndrome virus |
LO : | INIST-26272.354000114050090120 |
ID : | 04-0464714 |
Links to Exploration step
Pascal:04-0464714Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds</title>
<author><name sortKey="Chen, F" sort="Chen, F" uniqKey="Chen F" first="F." last="Chen">F. Chen</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, K H" sort="Chan, K H" uniqKey="Chan K" first="K. H." last="Chan">K. H. Chan</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jiang, Y" sort="Jiang, Y" uniqKey="Jiang Y" first="Y." last="Jiang">Y. Jiang</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Biology, Hong Kong Baptist University, Kowloon Tong</s1>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kao, R Y T" sort="Kao, R Y T" uniqKey="Kao R" first="R. Y. T." last="Kao">R. Y. T. Kao</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lu, H T" sort="Lu, H T" uniqKey="Lu H" first="H. T." last="Lu">H. T. Lu</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fan, K W" sort="Fan, K W" uniqKey="Fan K" first="K. W." last="Fan">K. W. Fan</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cheng, V C C" sort="Cheng, V C C" uniqKey="Cheng V" first="V. C. C." last="Cheng">V. C. C. Cheng</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tsui, W H W" sort="Tsui, W H W" uniqKey="Tsui W" first="W. H. W." last="Tsui">W. H. W. Tsui</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hung, I F N" sort="Hung, I F N" uniqKey="Hung I" first="I. F. N." last="Hung">I. F. N. Hung</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lee, T S W" sort="Lee, T S W" uniqKey="Lee T" first="T. S. W." last="Lee">T. S. W. Lee</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Guan, Y" sort="Guan, Y" uniqKey="Guan Y" first="Y." last="Guan">Y. Guan</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peiris, J S M" sort="Peiris, J S M" uniqKey="Peiris J" first="J. S. M." last="Peiris">J. S. M. Peiris</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yuen, K Y" sort="Yuen, K Y" uniqKey="Yuen K" first="K. Y." last="Yuen">K. Y. Yuen</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0464714</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0464714 INIST</idno>
<idno type="RBID">Pascal:04-0464714</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000822</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds</title>
<author><name sortKey="Chen, F" sort="Chen, F" uniqKey="Chen F" first="F." last="Chen">F. Chen</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, K H" sort="Chan, K H" uniqKey="Chan K" first="K. H." last="Chan">K. H. Chan</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jiang, Y" sort="Jiang, Y" uniqKey="Jiang Y" first="Y." last="Jiang">Y. Jiang</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Biology, Hong Kong Baptist University, Kowloon Tong</s1>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kao, R Y T" sort="Kao, R Y T" uniqKey="Kao R" first="R. Y. T." last="Kao">R. Y. T. Kao</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lu, H T" sort="Lu, H T" uniqKey="Lu H" first="H. T." last="Lu">H. T. Lu</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fan, K W" sort="Fan, K W" uniqKey="Fan K" first="K. W." last="Fan">K. W. Fan</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cheng, V C C" sort="Cheng, V C C" uniqKey="Cheng V" first="V. C. C." last="Cheng">V. C. C. Cheng</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tsui, W H W" sort="Tsui, W H W" uniqKey="Tsui W" first="W. H. W." last="Tsui">W. H. W. Tsui</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hung, I F N" sort="Hung, I F N" uniqKey="Hung I" first="I. F. N." last="Hung">I. F. N. Hung</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lee, T S W" sort="Lee, T S W" uniqKey="Lee T" first="T. S. W." last="Lee">T. S. W. Lee</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Guan, Y" sort="Guan, Y" uniqKey="Guan Y" first="Y." last="Guan">Y. Guan</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peiris, J S M" sort="Peiris, J S M" uniqKey="Peiris J" first="J. S. M." last="Peiris">J. S. M. Peiris</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yuen, K Y" sort="Yuen, K Y" uniqKey="Yuen K" first="K. Y." last="Yuen">K. Y. Yuen</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical virology</title>
<title level="j" type="abbreviated">J. clin. virol.</title>
<idno type="ISSN">1386-6532</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical virology</title>
<title level="j" type="abbreviated">J. clin. virol.</title>
<idno type="ISSN">1386-6532</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute</term>
<term>Antiviral</term>
<term>Clinical isolate</term>
<term>Coronavirus</term>
<term>Critically ill</term>
<term>Drug susceptibility test</term>
<term>Epidemic</term>
<term>In vitro</term>
<term>Microbiology</term>
<term>Respiratory tract</term>
<term>Sensitivity</term>
<term>Severe</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Virology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term>
<term>In vitro</term>
<term>Test sensibilité médicamenteuse</term>
<term>Sensibilité</term>
<term>Isolat clinique</term>
<term>Antiviral</term>
<term>Grave</term>
<term>Malade état grave</term>
<term>Aigu</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Voie respiratoire</term>
<term>Epidémie</term>
<term>Microbiologie</term>
<term>Virologie</term>
<term>Forme grave</term>
<term>Virus syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-la, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1386-6532</s0>
</fA01>
<fA03 i2="1"><s0>J. clin. virol.</s0>
</fA03>
<fA05><s2>31</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CHEN (F.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CHAN (K. H.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>JIANG (Y.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KAO (R. Y. T.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LU (H. T.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>FAN (K. W.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CHENG (V. C. C.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>TSUI (W. H. W.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>HUNG (I. F. N.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>LEE (T. S. W.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>GUAN (Y.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>PEIRIS (J. S. M.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>YUEN (K. Y.)</s1>
</fA11>
<fA14 i1="01"><s1>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Biology, Hong Kong Baptist University, Kowloon Tong</s1>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>69-75</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26272</s2>
<s5>354000114050090120</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0464714</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical virology</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-la, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02J</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>In vitro</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>In vitro</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>In vitro</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Test sensibilité médicamenteuse</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Drug susceptibility test</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Prueba sensibilidad medicamentosa</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Sensibilité</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Sensitivity</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sensibilidad</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Isolat clinique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Clinical isolate</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Aislado clinico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Grave</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Severe</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Grave</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Malade état grave</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Critically ill</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Enfermo estado grave</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Aigu</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Acute</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Agudo</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Voie respiratoire</s0>
<s5>67</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Respiratory tract</s0>
<s5>67</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Vía respiratoria</s0>
<s5>67</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Epidémie</s0>
<s5>68</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Epidemic</s0>
<s5>68</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Epidemia</s0>
<s5>68</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Microbiologie</s0>
<s5>69</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Microbiology</s0>
<s5>69</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Microbiología</s0>
<s5>69</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Virologie</s0>
<s5>70</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Virology</s0>
<s5>70</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Virología</s0>
<s5>70</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Forme grave</s0>
<s4>INC</s4>
<s5>79</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virose</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Viral disease</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virosis</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Infección</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>19</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>19</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>19</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>20</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>20</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>20</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Appareil respiratoire</s0>
<s5>22</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Respiratory system</s0>
<s5>22</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Aparato respiratorio</s0>
<s5>22</s5>
</fC07>
<fN21><s1>264</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0464714 INIST</NO>
<ET>In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds</ET>
<AU>CHEN (F.); CHAN (K. H.); JIANG (Y.); KAO (R. Y. T.); LU (H. T.); FAN (K. W.); CHENG (V. C. C.); TSUI (W. H. W.); HUNG (I. F. N.); LEE (T. S. W.); GUAN (Y.); PEIRIS (J. S. M.); YUEN (K. Y.)</AU>
<AF>Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Pokfulam Road/Hong-Kong (1 aut., 5 aut., 6 aut.); Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital/Hong-Kong (2 aut., 4 aut., 7 aut., 8 aut., 9 aut., 10 aut., 11 aut., 12 aut., 13 aut.); Department of Biology, Hong Kong Baptist University, Kowloon Tong/Hong-Kong (3 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Journal of clinical virology; ISSN 1386-6532; Pays-Bas; Da. 2004; Vol. 31; No. 1; Pp. 69-75; Bibl. 24 ref.</SO>
<LA>Anglais</LA>
<EA>Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-la, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics.</EA>
<CC>002A05C10; 002B05C02J</CC>
<FD>Coronavirus; In vitro; Test sensibilité médicamenteuse; Sensibilité; Isolat clinique; Antiviral; Grave; Malade état grave; Aigu; Syndrome respiratoire aigu sévère; Voie respiratoire; Epidémie; Microbiologie; Virologie; Forme grave; Virus syndrome respiratoire aigu sévère</FD>
<FG>Coronaviridae; Nidovirales; Virus; Virose; Infection; Appareil respiratoire pathologie; Poumon pathologie; Appareil respiratoire</FG>
<ED>Coronavirus; In vitro; Drug susceptibility test; Sensitivity; Clinical isolate; Antiviral; Severe; Critically ill; Acute; Severe acute respiratory syndrome; Respiratory tract; Epidemic; Microbiology; Virology; Severe acute respiratory syndrome virus</ED>
<EG>Coronaviridae; Nidovirales; Virus; Viral disease; Infection; Respiratory disease; Lung disease; Respiratory system</EG>
<SD>Coronavirus; In vitro; Prueba sensibilidad medicamentosa; Sensibilidad; Aislado clinico; Antiviral; Grave; Enfermo estado grave; Agudo; Síndrome respiratorio agudo severo; Vía respiratoria; Epidemia; Microbiología; Virología; Severe acute respiratory syndrome virus</SD>
<LO>INIST-26272.354000114050090120</LO>
<ID>04-0464714</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000822 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000822 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:04-0464714 |texte= In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |